340 related articles for article (PubMed ID: 35163032)
1. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
2. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
3. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
Batukbhai BDO; De Jesus-Acosta A
Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
6. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
Schmitt AM; Marinoni I; Blank A; Perren A
Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
[TBL] [Abstract][Full Text] [Related]
7. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in pancreatic neuroendocrine tumors.
Theochari MS; Syrigos KN; Saif MW
JOP; 2014 Mar; 15(2):138-9. PubMed ID: 24618438
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
10. Visual analytics identifies key miRNAs for differentiating peripancreatic paraganglioma and pancreatic neuroendocrine tumors.
Enguita JM; Díaz I; García D; Cubiella T; Chiara MD; Valdés N
Front Endocrinol (Lausanne); 2023; 14():1162725. PubMed ID: 37383401
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine pancreatic tumors: guidelines for management and update.
Burns WR; Edil BH
Curr Treat Options Oncol; 2012 Mar; 13(1):24-34. PubMed ID: 22198808
[TBL] [Abstract][Full Text] [Related]
13. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
Yan J; Yu S; Jia C; Li M; Chen J
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.
Daoud AZ; Mulholland EJ; Cole G; McCarthy HO
BMC Cancer; 2019 Nov; 19(1):1130. PubMed ID: 31752758
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review).
Subramani R; Gangwani L; Nandy SB; Arumugam A; Chattopadhyay M; Lakshmanaswamy R
Int J Oncol; 2015 Oct; 47(4):1203-10. PubMed ID: 26314882
[TBL] [Abstract][Full Text] [Related]
17. Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review.
Maiorano BA; Schinzari G; Chiloiro S; Visconti F; Milardi D; Bianchi A
Protein Pept Lett; 2020; 27(12):1276-1287. PubMed ID: 31804164
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.
Seyhan AA
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686149
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
